Vera Therapeutics, Inc.

The #IgANephropathy (#IgAN) treatment landscape has transformed over the last few years with new approved therapies and others in late-stage clinical development. The recently published MedNous article, authored by our SVP of Medical Affairs, Kerry Cooper, discusses Vera’s potentially first-to-market self-administered B cell modulation therapy within the evolving IgAN landscape. Read the full article to learn more! Published in the June edition of MedNous, a publication of Evernow Publishing Ltd.

Today we announced the appointment of David (DJ) Johnson as Chief Operating Officer at Vera. David's rich commercial and operational experience is a valuable addition to our executive team and will help drive the advancement of our clinical development programs. Read the full press release here:  https://lnkd.in/e5n6jd96 $VERA

On Sunday, Team Vera joined the National Kidney Foundation to sponsor the 2024 Northern California Kidney Walk at PayPal Park. This event brought the Northern California community together to fundraise for those affected by kidney disease. We were proud to walk alongside the kidney community and share the goal of achieving kidney health for all, one step at a time. #kidneydisease #IgANephropathy #IgAN

Team Vera made a splash at #APCN2024, where we sponsored a symposium describing the unmet need in #IgAN, insights into the role of BAFF and APRIL in IgAN pathogenesis, and emerging clinical data for atacicept, our investigational therapeutic. Visit veratx.com to learn more about our clinical program. #IgANephropathy

Looking back at #ERA24, we're grateful for the learnings, inspiration, and connections with nephrologists that we made in Stockholm. Thank you to the presenters of our two oral presentations—including ERA's top abstract—and our industry sponsored symposium, and to all who visited our booth and expressed interest in our clinical program for #IgANephropathy. See you next year!

We're participating in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on June 10-13. Our founder and CEO Marshall Fordyce, M.D. will present on Tuesday June 11 at 10:40am ET. For more details, read the press release: https://lnkd.in/eh7wpQU3 $VERA

We’re excited to announce that our investigational therapy, atacicept, has received FDA Breakthrough Therapy Designation for the treatment of #IgANephropathy! Read more: https://lnkd.in/eyGvcXhF

In ERA 2024's best-ranked abstract, we presented 72-week eGFR stabilization from our Phase 2b clinical trial for #IgANephropathy. We also showed rapid hematuria improvement and significantly higher hematuria resolution compared to placebo during the 36-week randomized period. Read the press release here: https://lnkd.in/eRcDMqd5 #ERA24

We're looking forward to connecting with nephrologists and discussing the latest advances in the field at the 61st ERA Congress, May 23-26 in Stockholm. Don't miss our presentations of Phase 2b ORIGIN results and our symposium about #IgANephropathy, and be sure to visit us at booth A400! Details on our presentations here: https://lnkd.in/e7J9wdf9 #ERA24

This #ClinicalTrialsDay and every day, we’re grateful to the clinical research professionals and trial participants who make clinical trials possible, including our ongoing Phase 3 trial, ORIGIN 3, in #IgANephropathy. Learn more about ORIGIN 3 here: https://lnkd.in/edM4NXT9